Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade

Daniel Grizelj Introduction Hims & Hers Health (NYSE:HIMS) has had an outstanding year so far, as the stock price is up 87.73% YTD. Q4'23 earnings gave investors a lot of confidence going forward, as the company exceeded expectations and raised its guidance. Q1'24 earnings also received a great reception, with the company posting great results once again. Weeks later, the company announced it would start selling compounded GLP-1 agonists to subscribers. Investors and the market responded well, as the stock ...